Why It Matters
China now accounts for approximately 30% of the global innovative-drug pipeline. In 2025, cross-border out-licensing deals hit a record US$135.7 billion across 157 transactions — roughly a third of global deal value. This is no longer a story about China as a manufacturing base for generics. Foreign pharmaceutical and biotech companies are actively choosing Chinese cities for R&D hubs, clinical trial sites, and scaled manufacturing operations.
Three metropolitan clusters now concentrate the majority of this activity. Each offers a distinct value proposition: Shanghai for discovery-stage R&D and regulatory speed, Beijing for clinical development and government-linked partnerships, and the Greater Bay Area (GBA) for scaled biologics manufacturing and Hong Kong-linked capital access. Picking the wrong cluster can cost 18-24 months in facility approvals and regulatory alignment.
The Details
Shanghai: The R&D Gateway
Shanghai’s Zhangjiang Hi-Tech Park (张江高科技园区, Zhāngjiāng gāokē jìshù yuánqū) houses over 1,000 biotech companies and accounts for 25% of China’s innovative-drug pipeline. The Shanghai Municipal Drug Administration processes clinical trial applications in 60 working days — compared to the national average of 90. Foreign companies including AstraZeneca, Roche, and Novartis maintain their China R&D headquarters here. Key advantages: proximity to Shanghai’s international airport (30 minutes), the largest concentration of CROs and CDMOs in Asia, and Shanghai’s pilot policies for expedited drug approvals under the Lingang New Area data-export whitelist framework.
Beijing: Clinical Development Hub
Beijing’s Zhongguancun Life Science Park (中关村生命科学园, Zhōngguāncūn shēngmìng kēxué yuán) benefits from proximity to the National Medical Products Administration (NMPA, 国家药品监督管理局) headquarters. Companies with NMPA-facing regulatory work — label approvals, post-market surveillance submissions, and IND applications in complex categories — save 2-4 months in review cycles by being in the same city as the regulator. Beijing also has China’s highest concentration of top-tier hospital clinical trial sites, with 37 GCP-certified hospitals versus Shanghai’s 24.
Greater Bay Area: Manufacturing & Commercial Scale
The GBA — centered on Shenzhen, Guangzhou, and Zhuhai — has positioned itself as China’s biologics manufacturing corridor. The area has attracted US$8.2 billion in foreign biopharma investment since 2022, led by biologics contract manufacturing. Shenzhen’s Pingshan District alone hosts 47 biotech manufacturing facilities, including the region’s first continuous-manufacturing biosimilar line. The GBA’s advantage is cost: manufacturing labor costs run 20-30% below Shanghai and Beijing, while industrial electricity rates are 15% lower. Access to Hong Kong’s capital markets provides a financing bridge that the other two clusters lack.
What You Should Do
- Match your business stage to the cluster. Early-stage R&D and discovery → Shanghai. Clinical development with NMPA regulatory needs → Beijing. Scaled biologics manufacturing → GBA.
- Check the Lingang data-export whitelist if your biopharma operations involve cross-border clinical data transfer. Shanghai Lingang’s new general data lists for biopharmaceuticals (released June 2026) cover clinical trial data, adverse event reporting, and pharmacovigilance data flows.
- Plan for 12-18 months from site selection to operational facility for a new R&D center. Manufacturing facilities in the GBA take 18-24 months for regulatory approvals across three different municipal governments.
One Data Point
The number to remember: US$135.7 billion — the value of China’s cross-border out-licensing deals in 2025. That is roughly one-third of global deal value, and it grew 22% from 2024. If you are not actively evaluating a China R&D location, you are leaving deal flow on the table.
Where to Go From Here
Read our case study on How Zai Lab Navigated China’s Biotech Regulatory Landscape for a real-world example of cluster selection and regulatory strategy. For a broader view of China’s life sciences ecosystem, see our organic certification guide — while focused on food/health products, the regulatory path illustrates the same NMPA-facing processes that biopharma investors encounter.
— China Gateway 360 —
Remote China market entry support, built around execution.
